Insiders who reported open-market trades in the last 12 months at the companies Cormorant Asset Management, LP files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Kristen Fortney - $4.22M in BIOA purchases and sales in the last 12 months
Shane Barton - $1.58M in BIOA purchases and sales in the last 12 months
Paul D. Rubin - $1.15M in BIOA purchases and sales in the last 12 months
Dov A. Md Goldstein - $532K in BIOA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Cormorant Asset Management, LP is an investment firm of BRIGHT MINDS BIOSCIENCES INC. (DRUG). InsiderAlpha holds 3 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Cormorant Asset Management, LP last file a Form 4?
The most recent primary Form 4 on record is dated 6 November 2024, one of 3 filings going back to 2024.
Has Cormorant Asset Management, LP been buying or selling stock?
Recorded transactions: 13 open-market purchases ($15.33M) and 0 open-market sales across all tracked filings.
Cormorant Asset Management, LP files SEC Form 4 reports at BRIGHT MINDS BIOSCIENCES INC. (DRUG). 3 SEC Form 4 filings on record, most recently on 6 November 2024. Most recent open-market trade: bought $4.00M of DRUG on 6 November 2024. Lifetime open-market purchases: $15.33M.
Recent transactions
14
The latest 14 SEC Form 4 transactions reported by Cormorant Asset Management, LP.
InsiderAlpha's records for Cormorant Asset Management, LP go back to 2024: 3 primary Form 4 filings, an average of 1.0 per year. The typical open-market purchase is $1.18M (13 buys totaling $15.33M). The largest single buy on record is $8.10M of BIOA in 2024. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
